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Background: Human parechoviruses (HPeVs) are among the most frequently detected picornaviruses in humans.
HPeVs are usually associated with mild gastrointestinal and respiratory symptoms with the exception of HPeV3
which causes neonatal sepsis and CNS infection. Previous studies showed various results in culturing different HPeV
genotypes, inducing only a low cytopathic effect (CPE).
Methods: In vitro growth characteristics of the different HPeV genotypes in a range of 10 different cell lines are
scored with CPE and measured in the supernatant by real time PCR. In the optimal cell line for each genotype a
standard neutralization assay with the available HPeV antibodies (Abs) was performed and scored by CPE and
measured by real time PCR.
Results: All six HPeV types were able to replicate on the RD99, A549, and Vero cell lines. HPeV1 was the only
genotype able to replicate on all cell lines. Most efficient growth of HPeV1, 2, 4, 5, and 6 was shown on the HT29
cell line, while HPeV3 was unable to replicate on HT29. In all cases viral replication could be measured by real time
PCR before CPE appeared. The polyclonal Abs available against HPeV1, 2, 4 and 5 all showed neutralization of their
respective genotype after 7 days with inhibition of >60% in real time PCR and full inhibition of CPE, although cross-
neutralization is shown. Replication of HPeV3 could only be inhibited by 12% by the anti-HPeV3 (aHPeV3) Ab and
no inhibition of CPE was shown after 7 days.
Conclusion: When replication is monitored by PCR, growth of HPeV genotypes 1 to 6 is supported by most of the
cell lines tested, where viral replication is measured before appearance of CPE. A combination of HT29 and Vero
cells would therefore support replication of all culturable HPeV types, so viral replication could be detected by PCR
within 3 days for all genotypes.
In addition, we showed efficient neutralization for HPeV1, 2, 4, 5, while cross- neutralization was shown between
these types, indicating possible common neutralizing epitopes. For HPeV3 no efficient (cross-) neutralization was
shown, indicating different neutralizing epitopes for HPeV3 compared to the other HPeV genotypes.
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Human Parechoviruses are single stranded RNA viruses
belonging to the Picornaviridae family. HPeVs are asso-
ciated with a wide range of clinical manifestations ran-
ging from gastrointestinal and respiratory symptoms to
more severe symptoms like central nervous system
(CNS) infections and neonatal sepsis [1-4]. Nowadays,
16 genotypes are known [5-10], HPeV1 and HPeV2
were first isolated in the 1950’s, whereas the third type
was only described in 2004. This late discovery of HPeV
could be due to difficulties of HPeVs detection in cell
culture, because of only a low induction of CPE, most
pronounced for HPeV3 and HPeV6. HPeV7 to 16 have
not been cultured in standard cell lines used in diag-
nostics. Previous studies showed various results in cul-
turing different HPeV genotypes. HPeV1 can be
cultured on various cell lines such as BSC-1, Caco2,
RD-18S, Vero, LLCMK2, RD99, HT29, tMK, and A549,
while other newer HPeVs induce only a low cytopathic
effect (CPE) on a limited number of cell lines [7,11,12].
For isolation of HPeV1, HPeV3 and HPeV6 from clin-
ical samples, Watanabe et al. used 8 different cell lines [7].
For HPeV3 it was shown that initial culturing of 3 clinical
specimen showed induction of CPE on the LLCMK2 cell
line after 14–18 days, albeit after passasing the virus to
Vero cells, CPE appeared after 4–5 days [1]. Benschop
et al. showed that the HT29 cell line is an efficient cell line
to propagate most HPeVs from clinical samples except for
HPeV3, which could only be isolated on A549 and Vero
cells [12]. None of the HPeVs could be detected by growth
on the HEL cell line, a cell line that is regularly used to cul-
ture enteroviruses (EVs). In addition it was shown that only
42% of clinical samples positive for HPeV by PCR could be
cultured, using 6 different cell lines [12]. With difficulties
in culturing HPeVs, there is also a limitation in isolation of
all the different strains for usage in HPeV serotyping assays.
Because HPeV detection with cell culture is laborious and
limited to HPeV1-6, PCRs targeting the 5’UTR are com-
monly used to diagnose HPeV infection [12-15]. Since the
5’UTR is highly conserved all HPeV types can be detected,
and this method is highly sensitive. However, cell culture is
still used as a diagnostic method in laboratories worldwide.
In addition, cell culture is imperative to obtain virus iso-
lates for further studies.
Although cell culture is a commonly used method in
diagnostics and research, HPeVs are difficult to culture for
many laboratories (personal communication). HPeVs cul-
ture characteristics have never been completely elucidated
in cell culture experiments. In this study we investigated
in vitro growth characteristics of different HPeV genotypes
by measuring viral RNA in the supernatant of a range of
cell lines by real time PCR. In addition, neutralization cap-
acities of available type-specific antibodies is tested in
in vitro cell culture.Results
Replication of HPeV1 to 6 on different cell lines
Virus growth characteristics of HPeV1 to 6 were deter-
mined on HT29, Caco-2, A549, RD99, Hep-2, Vero, BGM,
LLCMK2, SK-N-SH, and SH-SY-5Y by infection with a
fixed MOI (0.001). Replication was monitored in the cul-
ture supernatant at day 0, 1, 3, 7 and 10 by quantitative
RT-PCR, and CPE was scored at the same time points.
All six HPeV types were able to replicate on the RD99,
A549, and Vero cell lines (Figure 1, left panel). HPeV1 was
able to replicate on all cell lines. Rapid replication kinetics
reaching high virus titers were found on A549, RD99 and
BGM cells. Rapid replication kinetics with lower titers were
found on HT29, Caco-2 and LLCMK2, while replication
kinetics were slow on SH-SY-5Y and SK-N-SH cells. HPeV2
showed good replication on the HT29 cells, no replication
on the BGM cell line and only slow replication kinetics on
the other cell lines reaching low titers. HPeV3 reached high
titers on Vero, RD99, and Caco-2 cells but could also repli-
cate on SH-SY-5Y, SK-N-SH, LLCMK2, A549, and BGM.
HPeV3 was unable to replicate on HT29, while this cell line
supported the growth of all other HPeV types. HPeV1 and
3 were the only two strains able to replicate on BGM cells.
Replication kinetics of types HPeV4 to 6 on the cell lines
supporting their growth were mostly slower and/or reached
lower virus titers than for HPeV1 or 3. HPeV4 and 5
showed good replication on the HT29 and RD99 cells, and
only low replication on the A549, Caco2 (HPeV4), SH-SY
-5Y (HPeV5), SK-N-SH and the Vero cells. HPeV6 showed
inefficient replication: only slow replication was found in
A549, RD99, Vero, HT29 and SH-SY-5Y. None of the
HPeV types were able to replicate on Hep-2 cells (data not
shown). On the Caco-2 cells CPE induction was limited to
HPeV1 and 3, appearing in 7 to 10 days, while viral replica-
tion of HPeV2 and 4 could also been shown within 6 days
by real time PCR . For HPeV3 CPE appears after 7 days
only on the Vero cell line, while viral replication could be
measured within one day with PCR.
Overall, replication of HPeV1 to 6 was observed in most
cell lines including neural cell lines, although with different
kinetics. With respect to replication on the human-derived
cell lines, differences were most pronounced in the A549
with highest growth kinetics of the HPeV1, and in the
HT29 where all genotypes could replicate except HPeV3.
There was no cell line exclusively supporting replication of
a specific HPeV genotype.
Neutralization capacity
Polyclonal Abs available against HPeV1 to 5 were tested
for neutralization capacity against HPeV1 to 6 by inhibition
of CPE in cell culture (Table 1) and the inhibition was
measured by real-time PCR (Table 2) at day 3 (Additional
file 1: Table S1,S2) and day 7 (Tables 1,2). Only the aHPeV2
Ab fully neutralized its respective genotype without any
Figure 1 (See legend on next page.)
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Figure 1 Replication kinetics of HPeV1 to 6. Growth kinetics of laboratory adapted HPeV1 to 6 on different cell lines including appearance of
CPE at days 0, 1, 3, 7 and 10. Cells were infected with HPeVs at a MOI 0.001 and viral RNA was detected in the supernatant with RT-PCR at days 0,
1, 3, 7 and 10. The 10log virus copies were calculated with a standard curve, and the input virus copies per PCR at day 0 was subtracted. HPeV1:
orange line, HPeV2: red line, HPeV3: black line, HPeV4: green line, HPeV5: yellow line, HPeV6: blue line. CPE was scored as positive (+), negative (−)
and dead cells (X).
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cross-neutralization, with the HPeV4 and HPeV5 proto-
types showing 60% inhibition of replication and reduced
CPEs from 4+ to 2+. The aHPeV1 Ab also inhibited repli-
cation of HPeV6 by 27%, showing a reduction in CPE from
4+ to 3+. The aHPeV4 Ab inhibited replication of both
HPeV4 and HPeV5 to the same extent (56-60%) with full
inhibition of CPE formation, while the minor replication
inhibition up to 16% for the other HPeV types was not vis-
ible by reduction of CPE. The aHPeV5 Ab showed high
cross-neutralization with HPeV1 and lower with HPeV4
and HPeV6.
The aHPeV3 Ab inhibited replication of our laboratory
prototype HPeV3-150237 only by 12%, while no reduction
of CPE was shown after 7 days. Culturing for 3 or 7 days
before measuring replication by PCR did not make a differ-
ence (Additional file 1: Table S2).
Discussion
This study shows different replication kinetics of the
culturable HPeV genotypes 1 to 6 on a set of different cell
lines with real time PCR. Previously, difficulties have been
encountered in culturing HPeVs, especially for HPeV3 and
HPeV6 [1,7,12], which could only be propagated on a lim-
ited number of cell lines showing poor production of CPE.
Replication monitored by PCR shows that growth of HPeV
genotypes 1 to 6 was supported by most of the cell lines
tested, and by comparing replication kinetics measured
by PCR and seen by CPE, viral replication can be measured
before CPE appears in the infected cell line, while some-
times CPE does not occur at all. In three of the nine cellTable 1 Neutralization of HPeV1 to 6 by polyclonal Abs, read
aHPeV1-Ab2 aHPeV2-Ab2 aH
HPeV1- Harris1 - * 4+
HPeV2- 7513121 4+ -
HPeV3- 1502371 4+ 4+
HPeV4- 2511761 2+ 4+
HPeV5- 5523221 2+ 4+
HPeV6- 5503891 3+ 4+
1 100TCID50 infection on HT29 (HPeV1, 2, 4, 5) and Vero (HPeV3) cells.
2 Ab dilution 1:100.
* - no CPE.
1+ 0- 25% CPE.
2+ 25-50% CPE.
3+ 50-75% CPE.
4+ 75-100% CPE.lines (Vero, RD99 and A549) all six prototypes could be
propagated. All HPeV1 to 6 genotypes show replication
with high viral titers on the RD99 cell line, but CPE is
hardly seen. The combination of HT29 and Vero cells is
suitable to detect all culturable HPeV types by CPE, where
viral replication could be detected with PCR within 3 days
for all genotypes. By measuring replication by PCR we
showed that HPeV6 was able to replicate on 5 of the 9 cell
lines tested and HPeV3 on all cell lines except HT29. In
contrast, HPeV3 was able to replicate on the Caco-2 gastro-
intestinal cell line. This difference can be due to the fact
that Caco-2 cells are known for their ability to differentiate
to a more fetal-like phenotype rather than adult ileal
enterocytes, resulting in different receptor expression
[16,17]. Between the different genotypes, replication kinet-
ics were found to differ between cell lines, however there
was no cell line exclusively supporting replication of a spe-
cific HPeV genotype. All cell lines used in our study are
continuously growing cell lines obtained from tumours
that do not necessarily represent the tissue from which
they originated. To get better representation of the in vivo
replication of the different genotypes, primary cell systems
need to be set up.
In our study we showed that the available HPeV Abs
neutralized their respective genotype with high percent-
ages of inhibition after 7 days. Thereby we show that in-
hibition of viral replication can already be measured after
3 days with similar inhibition percentages, while CPE is
only starting at that time for some genotypes. Measuring
neutralization by reduction of CPE or replication inhib-
ition by PCR is comparable: inhibition of replication >out of CPE at day 7 post infection
CPE score day 7
PeV3 Ab2 aHPeV4 Ab2 aHPeV5 Ab2 No Ab
4+ 4+ - 4+
4+ 4+ 4+ 4+
4+ 4+ 4+ 4+
4+ - 1+ 4+
4+ - - 4+
4+ 4+ 2+ 4+
Table 2 Neutralization of HPeV1 to 6 by polyclonal Abs, percentage of inhibition measured by real time PCR at day 7
post infection
Percentage inhibition in real-time PCR day7
aHPeV1-Ab2 aHPeV2-Ab2 aHPeV3 Ab2 aHPeV4 Ab2 aHPeV5 Ab2
HPeV1- Harris1 85 6 7 6 84
HPeV2- 7513121 8 80 1 5 2
HPeV3- 1502371 2 0 12 5 5
HPeV4- 2511761 39 0 0 64 14
HPeV5- 5523221 58 0 0 54 63
HPeV6- 5503891 28 0 1 0 30
1 100TCID50 infection on HT29 (HPeV1, 2, 4, 5) and Vero (HPeV3) cells.
2 Ab dilution 1:100.
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between 20-60% gives reduction of 1+ or 2+ of CPE and
inhibition of <20% shows no reduction of CPE. By PCR as
well as by CPE read out, we showed cross neutralization of
presumably type-specific polyclonal Abs, while neutralizing
Abs for picornaviruses are considered to be serotype-
specific. However, cross-neutralization has been reported
before as shown in two studies with CAV9 and HPeV1
[18,19]. For EVs the main immunogenic region is the cap-
sid protein VP1. In both CAV9 and HPeV1 the C-terminus
of the capsid protein VP1 contains the arginine- glycine-
aspartic acid (RGD), which has been shown to be an im-
portant antigenic site. Although by peptide scanning a
highly immunodominant epitope has been recognized in
the N-terminal region of the VP0 capsid, of which the neu-
tralizing Abs against VP0 showed high reactivity with
HPeV1. Abs raised against these different antigenic sites
possibly differ in their ability to cross- neutralize HPeV in-
fections. Reinfections in children aged 0–3 years are
reported, showing a lower incidence of a second infection
and infections within the first year after the initial infec-
tions were rare [20,21]. This lower incidence of a second
infection in children is possibly due to partial cross-
neutralization. Thereby HPeV infections in adults are
hardly found.
For HPeV, the available Abs are all polyclonal obtained
from immunization of animals, hence the presence of Abs
that can bind to common epitopes is expected. Generating
seroprevalence data this cross- neutralization should be
taken in account. As we have shown before, the available
aHPeV3 Ab A308-99 was not able to neutralize our
HPeV3-150237 strain despite efficient binding [22]. The
lack of neutralisation of HPeV3 with the Japanese Ab could
indicate that the antibody has partly lost its potency. How-
ever, previously we showed that after HPeV3 infection in
two different donors the obtained sera did not neutralize
HPeV3. Further research is needed to confirm whether
HPeV3 is indeed difficult to neutralize, or whether these
results are based on in vitro artefacts such as a defect anti-
body or the influence of the cell line used for in vitro
neutralization assays. It could be that the HPeV3 virusstructure does not permit Abs to reach the neutralizing
epitope, but more research is needed to elucidate the
mechanism of HPeV3 neutralization.
In summary, we showed that when replication is moni-
tored by PCR, growth of HPeV genotypes 1 to 6 is sup-
ported by most of the cell lines tested. Viral replication
could be measured before CPE appeared in the infected cell
line. For HPeV1, 2, 4, 5 and 6 neutralization is shown with
high inhibition of viral replication; with cross neutralization
shown, in contrast the available HPeV3 Ab shows almost
no (cross-) neutralization. More research needs to be done




For virus culture, the following cell lines were used: human
colon carcinoma (HT29), human colon adenocarcinoma
(Caco-2), human lung carcinoma (A549, kindly provided
by the University Medical Center, Leiden), rhabdomyosar-
coma (RD99), epidermoid carcinoma of the larynx (Hep-2),
African green monkey kidney (Vero), buffalo green monkey
kidney (BGM, kindly provided by Dr. van Kuppeveld,
St. Radboud University, Nijmegen), rhesus monkey kidney
(LLCMK2, kindly provided by the Municipal Health
Services, Rotterdam), and human neuroblastomas (SK-N-
SH, kindly provided by Dr. Scheper, department of
Neurogenetics, Academic Medical Center; SH-SY-5Y, kindly
provided by Dr. Tauriainen, University of Tampere,
Finland). The cells were maintained in Eagle’s Minimum
Essential Medium (EMEM) supplemented with L-glutamic
acid (0.2X), non essential amino acid (1X), streptomycin
(0.1 μg/ml) and ampicillin (0.1 μg/ml). For HT29, A549,
RD99, Hep-2, Vero, LLCMK2, and BGM the medium was
supplemented with 8% heat-inactivated Fetal Calf Serum
(FCS) and for the Caco-2 cell line with 20% heat-inactivated
FCS. The human neuroblastoma cell lines were cultured in
Dulbecco’s MEM and supplemented with 10% heat-
inactivated FCS, L-glutamic acid (0.2X), non essential
amino acid (1X), streptomycin (0.1 μg/ml) and ampicillin
(0.1 μg/ml).
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The following HPeV strains were used as prototypes:
HPeV1A Harris, HPeV2-751312, HPeV3-150237, HPeV4-
251176, HPeV5-552322 and HPeV6-550389 [12,23,24].
HPeV1-Harris and the HPeV2-751312 strains were provided
by the Dutch National Institute for Public Health and the
Environment (RIVM), Bilthoven, the Netherlands, and pas-
saged to obtain a sufficient virus stock. The HPeV3 to 6 were
isolated from stool passaged two to three times to obtain suf-
ficient virus stocks. HPeV1, 2, 4, and 5 were cultured in the
HT29 cell line, HPeV3 in the Vero cell line and HPeV6 in
the RD99 cell line and the virus working stocks were stored
in aliquots at −80°C. The virus concentration was deter-
mined by the median tissue culture infective dose (TCID50)
and calculated by the Reed and Muench method [25].
Antibodies
The anti-HPeV (aHPeV) Abs against HPeV1 (Harris) and 2
(Williamson) were obtained from a rabbit Ab pool prepared
at the RIVM. The aHPeV3 (A308-99) Ab was a kind gift
from Dr. Shimizu, National Institute of Infectious Diseases,
Tokyo, Japan, prepared as pooled guinea pig serum [10].
The aHPeV4 (S2592) and aHPeV5 (S2663) Abs were a kind
gift from Dr. Schnurr, Viral and Rickettsial Disease Labora-
tory, California Department of Health Services, Berkeley
USA, prepared as Armenian Hamster pooled serum [26].Virus replication curves
Monolayers of the different cell lines were cultured in 24
wells plates (Cellstar) with 1 ml medium and incubated at
37°C, 5% CO2. At day 0 the cell lines with a confluence
of ~80% were infected with HPeV at a multiplicity of infec-
tion (MOI) of 0.001 in a volume of 200 μl culture medium
for two hours, after which the non absorbed virus was re-
moved and replaced with 1 ml maintenance medium
(EMEM 2%, DMEM 2%) and incubated for 10 days. The
low MOI is chosen to elucidate the entire process of the
infection cycle of HPeV in cell culture. Twenty μl culture
supernatant was removed for RNA extraction and quanti-
tative RT-PCR detection at days 0, 1, 3, 7 and 10. The
supernatant was extracted by automatic extraction using
the total nucleic acid isolation kit with the MagnaPure LC
instrument® (Roche Diagnostics). The RNA was eluted in
50 μl elution buffer and reverse transcribed as described
previously [12]. Five μl of cDNA was used for real-time
PCR using the LC480 (Roche Diagnostics) [12]. The virus
copies per PCR were calculated with a standard curve as
described previously [13]. The virus replication was normal-
ized to the number of virus copies per PCR on day 0 (input
virus). At day 10, supernatants were genotyped to confirm
the input virus strain by VP1 genotyping as described before
[13]. All replication experiments were first optimized with
different MOI and all experiments were done in two-fold.Neutralization assay
Abs were mixed with the different HPeV1 to 6 virus sus-
pension containing 100 TCID50/50 μl. Ab dilutions of
aHPeV1, aHPeV2, aHPeV3, aHPeV4 and 5 (1:100) were
used for end-point neutralization of 100TCID50 HPeV1 to
6. Mixtures were incubated at 37°C for 1 hr, and were used
to inoculate HT29 cells (HPeV1, 2, 4, 5, and 6) and Vero
cells (HPeV3) on a 96-wells plate (200 μl). Virus, cell and
Ab controls were included as positive and negative control.
The cells were examined for the appearance of CPE every
24hrs for 3 and 7 days and amount of viral copies were de-
fined by real time PCR.
Additional file
Additional file 1: Table S1. Neutralization of HPeV1 to 6 by polyclonal
Abs, read out of CPE at day 3 post infection. Table S2. Neutralization of
HPeV1 to 6 by polyclonal Abs, percentage of inhibition measured by real
time PCR at day 3 post infection.
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